A small city in Brazil that made national headlines by offering weight-loss injections through its public health system must now freeze its operations. A São Paulo court ordered an immediate halt to the program following a legal challenge by pharmaceutical giant Eli Lilly.
What Happened
The municipality of Urupês, located in inner São Paulo state, launched a pioneer public treatment program for obesity early this year. Dubbed "Bolsa Mounjaro" on social media, the project aimed to treat 400 low-income residents, prioritizing patients awaiting bariatric surgery.
Instead of purchasing Eli Lilly's official Mounjaro pens—which cost around R$ 1,500 (approx. $260 USD) per dose—the city bought a compounded version of the active ingredient, tirzepatide, from a licensed compounding pharmacy for about R$ 900 per vial. The R$ 306,000 purchase was funded through parliamentary funds provided by Federal Deputy Tiririca.
Why the Lawsuit Started
Eli Lilly filed a lawsuit arguing that Urupês violated health regulations set by Brazil's federal health agency, Anvisa. Under national health guidelines, compounding tirzepatide is only permitted as an exception for individualized patient prescriptions, not for bulk or standardized municipal purchasing.
The court issued a preliminary injunction ordering Urupês to suspend all applications and purchases of the compounded drug immediately, imposing a daily fine of R$ 10,000 for non-compliance. A subsequent appeal by the city was rejected, with the court noting that while compounded purchasing is blocked, the city remains legally free to acquire official Mounjaro directly from Eli Lilly.
Local Impact and What's Next
City officials argue that the court's decision prioritizes commercial pharmaceutical interests over public health access. According to municipal leaders, the initiative provided essential multidisciplinary care to vulnerable residents who could never afford private weight-loss treatments.
Urupês plans to file additional appeals to reinstate the initiative. In the meantime, treatment remains frozen for hundreds of patients, leaving the future of Brazil’s first municipal weight-loss drug program uncertain.
/https://i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2026/i/G/U0zBQIRzCVX6fx0J5azQ/pexels-itslauravillela-33327682.jpg)


